TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01749579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
Study: NCT03602469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus 3 mL of 0.9% saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine-magnesium
Description: Ultrasound-guided suprascapular nerve block will be performed using 7 mL of 0.5% bupivacaine plus magnesium sulfate 10% (3 ml) (total 10mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Using propofol 1.5-2.5 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Using propofol 1.5-2.5 mg/kg

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided suprascapular nerve block
Study: NCT00639418

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.

Intervention type: BIOLOGICAL
Intervention: Influenza vaccination
Description: This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
Study: NCT00649779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albuterol sulfate extended-release 8 mg tablets
Description: 8mg, single dose fasting
Study: NCT01083706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Given SC or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00649779

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VoSpire™ ER 8 mg tablets
Description: 8mg, single dose fasting
Study: NCT01247077

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: selenium
Description: 200 ug selenium once daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT02125292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine
Study: NCT02392507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Administered IV
Study: NCT03602469

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound-guided suprascapular nerve block

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane 0.7-1.5 MAC in 40% oxygen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane 0.7-1.5 MAC in 40% oxygen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium
Description: Rocuronium 0.6 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium
Description: Rocuronium 0.6 mg/kg
Study: NCT03904238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy for Hypersomnia (CBT-H)
Description: The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., I cannot live a full life because of my illness), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy for Hypersomnia (CBT-H)
Description: The CBT-H intervention consists of 6 weekly sessions that are conducted either individually or in small groups. Each session is expected to last about 45 to 60 minutes and will be delivered a study therapist using live videoconferencing or in-person. The treatment package consists of cognitive and behavioral modules that include education about hypersomnia, coping skills training, emotion regulation regarding the perceived limitations of living with chronic hypersomnia (e.g., I cannot live a full life because of my illness), and behavioral techniques using scheduled naps, sleep hygiene, and regularizing sleep schedules at night which are on the current optional recommendations for hypersomnia.
Study: NCT00973739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.~Children/adolescents (\<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)~Adults (\>=18 years of age): 1,500 mg PO (6 tablets once daily)~Duration: Up to 12 months, depending on treatment response.
Study: NCT00561756

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: plasmid DNA vaccine therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Study: NCT02762266

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial Chemoembolization
Description: Undergo TACE

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: embolic agent
Description: . Acceptable embolic agents include:~* Gelatin sponge (gelfoam)~* Polyvinyl alcohol (PVA) particles~* Microspheres / Embolic beads

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipiodol
Study: NCT03935009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush Curaprox 5460 ultra soft
Description: Soft manual toothbrush (Curaprox 5460 ultra soft) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chumswill will be used to brush teeth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual toothbrush Curaprox 5460 ultra soft
Description: Soft manual toothbrush (Curaprox 5460 ultra soft) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Chomper Chumswill will be used to brush teeth.
Study: NCT01609413

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AlgaeCal
Description: One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
Study: NCT03935009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electric toothbrush Play Smart Brush N°1
Description: Electric toothbrush (Play Smart Brush N°1) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App will be used to brush teeth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electric toothbrush Play Smart Brush N°1
Description: Electric toothbrush (Play Smart Brush N°1) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Playbrush App will be used to brush teeth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electric toothbrush Play Smart Brush N°2
Description: Electric toothbrush (Play Smart Brush N°2) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia will be used to brush teeth.
Study: NCT02392507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study: NCT03935009

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Electric toothbrush Play Smart Brush N°2
Description: Electric toothbrush (Play Smart Brush N°2) and Jordan Miracle Flossers floss, Curaprox toothpaste 1450 and mobile phone application Utoothia will be used to brush teeth.
Study: NCT00623727

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rFVIII-FS/pegylated liposomes (BAY79-4980)
Description: 35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
Study: NCT01509183

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Propeller Health System (formerly Asthmapolis System)
Description: The Propeller (formerly Asthmapolis) system works through the provision of information to patients and their providers. With the Propeller (formerly Asthmapolis) device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Propeller (formerly Asthmapolis) where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
Study: NCT00606788

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SmartCare/PS (Automated Weaning)
Description: Patients received computer-driven protocolized weaning
Study: NCT00623727

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rFVIII-FS/WFI (BAY14-2222)
Description: 25 IU/kg body weight intravenous 3x/week for 52 weeks
Study: NCT00951665

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab [Perjeta]
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab [Perjeta]
Description: Intravenous repeating dose
Study: NCT00606788

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional weaning
Description: Patients received physician-directed non-protocolized weaning
Study: NCT03783936

Intervention type: DRUG
Group type: OTHER
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2
Study: NCT03016273

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: creation of bladder flap
Description: Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
Study: NCT03751007

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG019 - Low Dose
Description: Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG019 - Low Dose
Description: Solid, orally administered capsule - 2 capsules per day for 1 day (single dose) or 8 weeks (repeat dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teplizumab
Description: Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teplizumab
Description: Daily IV infusions of Teplizumab during the first 12 days of AG019 treatment. Total cumulative dose is approximately 17mg (dose calculation based on body surface area).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-AG019
Description: Formulated identically to AG019 with the active ingredient removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-AG019
Description: Formulated identically to AG019 with the active ingredient removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Teplizumab
Description: Formulated identically to teplizumab with the active ingredient removed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo-Teplizumab
Description: Formulated identically to teplizumab with the active ingredient removed.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG019 - High Dose
Description: Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG019 - High Dose
Description: Solid, orally administered capsule - 6 capsules per day for 1 day (single dose) or 8 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG019 - High Dose
Description: Solid, orally administered capsule - 6 capsules per day for 8 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AG019 - High Dose
Description: Solid, orally administered capsule - 6 capsules per day for 8 weeks.
Study: NCT03281876

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NTHi Mcat investigational vaccine (GSK3277511A)
Description: Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
Study: NCT03783936

Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin
Description: Leucovorin 400 mg/m2
Study: NCT00334373

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post conditioning
Description: 4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
Study: NCT03783936

Intervention type: DRUG
Group type: OTHER
Intervention: 5 fluorouracil
Description: 5 fluorouracil 400 mg/m2 bolus and 2400 mg/m2 continuous infusion

Intervention type: DRUG
Group type: OTHER
Intervention: Trastuzumab
Description: Trastuzumab 6 mg/kg loading dose C1D1 then 4 mg/kg Day 1
Study: NCT00334373

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Post conditioning
Description: 4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
Study: NCT01932918

Intervention type: DRUG
Intervention: Patient controlled analgesia
Description: 1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.

Intervention type: DRUG
Intervention: Patient controlled analgesia
Description: 1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.

Intervention type: DRUG
Intervention: Patient controlled analgesia
Description: 1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.

Intervention type: DRUG
Intervention: Patient controlled analgesia
Description: 1. PCA with morphine in liver transplant:~   Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.~2. PCA with morphine and ketorolac:~   Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.~3. Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.~4. PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients.
Study: NCT01533012

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure difference
Description: Peak inspiratory pressures difference between two lungs
Study: NCT01609413

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caltrate 600
Description: One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
Study: NCT03031067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine perfusion
Description: The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine perfusion
Description: The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.~Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer.
Study: NCT04345094

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hexylresourcinol
Description: Emulsion containing hexylresorcinol as an active
Study: NCT03783936

Intervention type: DRUG
Group type: OTHER
Intervention: Avelumab
Description: Avelumab 800 mg
Study: NCT04345094

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydroquinone
Description: Emulsions containing hydroquinone as an active
Study: NCT00721539

Intervention type: DEVICE
Group type: OTHER
Intervention: da Vinci Surgical Robot Platform
Description: daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transoral Robotic Surgery
Description: Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
Study: NCT03377933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compound Lactobacillus acidophilus
Description: Compound Lactobacillus acidophilus Tablet
Study: NCT01927055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droxidopa
Description: Droxidopa at 100 mg, 200 mg, 300 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match droxidopa capsules and strength designations
Study: NCT02407899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: Take saxagliptin tablet 5mg p.o. qd. for 104 weeks after randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Take vitamin D drops 2000 IU p.o. qd. for 104 weeks after randomization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: For optimal control of patients' glucose, researchers can initiate insulin therapy at any time in this trial, choose any brands of insulin after discussion with the patient.
Study: NCT04851769

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor plus statin
Description: Patients in the alirocumab arm will receive alirocumab 75 mg Q2W added to statin therapy (atorvastatin 20 mg/day or rosuvastatin 10mg/day).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard statin therapy
Description: Patients will continue to receive atorvastatin 20 mg/day or rosuvastatin 10 mg/day.